Novel Therapies for Relapsed or Refractory HER2-Positive Metastatic Breast Cancer

Register now to attend this live and interactive, CME-certified Webinar on new developments in the care of patients with HER2-positive advanced breast cancer. Participants will get up-to-date insights from expert faculty novel therapeutic agents and strategies utilizing antibody–drug conjugates for patients after failure of standard-of-care treatments.

During the live program, you will have multiple opportunities to interact with the presenting faculty through interactive patient case scenarios and an audience question and answer session.

Thank you for your interest in attending the Clinical Care Options’ (CCO) symposium, “Novel Therapies for Relapsed or Refractory HER2-Positive Metastatic Breast Cancer and Beyond.” Due to the global impact of COVID-19, ESMO organizers have decided to host the ESMO Breast Cancer 2020 Meeting in a virtual format.

Therefore, our planned live satellite symposium will now be available as an on-demand Webinar that will be featured as part of the ESMO Breast Congress virtual meeting. In addition, the program faculty will conduct an interactive, live Webinar during which you will be able to text questions directly to the faculty and the planned agenda allows time for the faculty to discuss and answer your submitted questions.

We hope that you will take advantage of both of these learning opportunities and in particular, the program faculty look forward to having you join them for the live Webinar.

Thank you,
CCO Member Services


Program Overview (5 min)

Novel Therapies for Relapsed/Refractory HER2 MBC (30 min)

  • New anti-HER2-directed antibody–drug conjugates
  • Future directions for antibody-based therapies for HER2-positive breast cancer

Case Discussions: Management of Relapsed/Refractory HER2 MBC Today (20 min)

  • Selecting treatment for patients HER2-positive MBC following relapse on traditional HER2 targeted agents
  • Selecting treatment for patients with previously treated HER2-positive MBC and CNS metastases

Question and Answer Session (5 min)


Date / Time
Event Details


Program Director
Adam Brufsky, MD

Professor of Medicine
University of Pittsburgh School of Medicine
Associate Chief, Hematology-Oncology
University of Pittsburgh Cancer Institute
Pittsburgh, Pennsylvania USA

Thomas Bachelot, MD, PhD

Chair, Unicancer Breast Group - UCBG
Breast Cancer Unit
Medical Oncology
Centre Leon Bérard
Lyon, France

Cristina Saura, MD, PhD

Medicine and Surgery/Medical Oncology
Universidad Universitat Autònoma Barcelona and Vall d’Hebron Institute of Oncology (VHIO)
Head, Breast Cancer Program
Medical Oncology
Vall d’Hebrón University Hospital
Barcelona, Spain

Goal Statement
The goal of this activity is to improve the knowledge, competence and performance of learners to integrate new and emerging therapies into treatment for HER2-positive breast cancer treatment.

Target Audience 
This program is intended for global medical oncologists and other healthcare providers who care for patients with breast cancer.

Learning Objectives 

  • Integrate recent practice-changing advances in the treatment of HER2-positive MBC
  • Identify new and emerging therapies for third line and beyond for HER2-positive MBC
  • Assess clinical trial results for novel HER2-directed and targeted therapies in this setting


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation 

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.